Table 3.
Patient outcomes adjusted for T-stage, iPSA, and GS
| Dose group |
||||||||
|---|---|---|---|---|---|---|---|---|
| <70 Gy (n = 43) | 70–74.9 Gy (n = 552) | 75–79.9 Gy (n = 568) | ≥80 Gy (n = 367) | |||||
| ASTRO adjusted | 5-year | 8-year | 5-year | 8-year | 5-year | 8-year | 5-year | 8-year |
| FFBF | 60% | 54% | 68% | 60% | 76% | 69% | 84% | 81%* |
| No. at risk | 17 | 5 | 208 | 69 | 155 | 37 | 72 | NA |
| Nadir + 2 adjusted | 5-year | 8-year | 5-year | 8-year | 5-year | 8-year | 5-year | 8-year |
| FFBF | 70% | 51% | 81% | 64% | 83% | 67% | 89% | 78%* |
| No. at risk | 25 | 9 | 264 | 94 | 205 | 50 | 97 | NA |
| Adjusted | 5-year | 10-year | 5-year | 10-year | 5-year | 10-year | 5-year | 10-year |
| FFDM | 96% | 93% | 97% | 93% | 98% | 95% | 98% | 96%* |
| No. at risk | 32 | 16 | 413 | 72 | 319 | 47 | 119 | NA |
| Adjusted | 10-year | 10-year | 10-year | 10-year | ||||
| OM | 49% | 37% | 31% | 36% | ||||
| No. at risk | 16 | 78 | 48 | 9 | ||||
Abreviations: ASTRO = American Society for Therapeutic Radiology and Oncology; FFBF = freedom from biochemical failure; FFDM = freedom from distant metastases; NA = not available; OM = overall mortality.
*
Estimated.